

Ann J Hessel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1183424/publications.pdf>

Version: 2024-02-01

37
papers

4,681
citations

394421

19
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

3938
citing authors

#	ARTICLE	IF	CITATIONS
1	Fc receptor but not complement binding is important in antibody protection against HIV. <i>Nature</i> , 2007, 449, 101-104.	27.8	828
2	Structural definition of a conserved neutralization epitope on HIV-1 gp120. <i>Nature</i> , 2007, 445, 732-737.	27.8	715
3	Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro. <i>Journal of Virology</i> , 2001, 75, 8340-8347.	3.4	649
4	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. <i>Nature Medicine</i> , 2009, 15, 951-954.	30.7	509
5	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. <i>PLoS Pathogens</i> , 2009, 5, e1000433.	4.7	475
6	Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIV _{Ba-L} . <i>Journal of Virology</i> , 2010, 84, 1302-1313.	3.4	296
7	Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11181-11186.	7.1	243
8	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , 2016, 22, 362-368.	30.7	163
9	Use of broadly neutralizing antibodies for HIV prevention. <i>Immunological Reviews</i> , 2017, 275, 296-312.	6.0	131
10	A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc γ RIIIa-Mediated Antiviral Activity <i>In Vitro</i> but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. <i>Journal of Virology</i> , 2012, 86, 6189-6196.	3.4	110
11	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. <i>Journal of Immunology</i> , 2016, 196, 3064-3078.	0.8	56
12	Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2014, 88, 12968-12981.	3.4	51
13	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. <i>Journal of Virology</i> , 2018, 92, .	3.4	51
14	Inhibition of HIV-1 Infectivity and Epithelial Cell Transfer by Human Monoclonal IgG and IgA Antibodies Carrying the b12 V Region. <i>Journal of Immunology</i> , 2007, 179, 3144-3152.	0.8	40
15	Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits. <i>Journal of Virology</i> , 2014, 88, 12949-12967.	3.4	37
16	Single-dose bNAbs cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. <i>Nature Communications</i> , 2020, 11, 70.	12.8	37
17	Passive and active antibody studies in primates to inform HIV vaccines. <i>Expert Review of Vaccines</i> , 2018, 17, 1-18.	4.4	36
18	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. <i>Cell Reports</i> , 2019, 28, 877-895.e6.	6.4	36

#	ARTICLE	IF	CITATIONS
19	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. <i>Frontiers in Public Health</i> , 2021, 9, 690017.	2.7	26
20	Neutralizing Antibodies and Control of HIV: Moves and Countermoves. <i>Current HIV/AIDS Reports</i> , 2012, 9, 64-72.	3.1	23
21	Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. <i>Vaccine</i> , 2016, 34, 2713-2721.	3.8	23
22	Simplifying the synthesis of SIgA: Combination of dlG _A and rhSC using affinity chromatography. <i>Methods</i> , 2014, 65, 127-132.	3.8	20
23	Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. <i>Nature Communications</i> , 2022, 13, 662.	12.8	18
24	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. <i>Vaccine</i> , 2017, 35, 1464-1473.	3.8	15
25	Efficacy of silk fibroin biomaterial vehicle for <i>in vivo</i> mucosal delivery of Griffithsin and protection against HIV and SHIV infection <i>ex vivo</i> . <i>Journal of the International AIDS Society</i> , 2020, 23, e25628.	3.0	14
26	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
27	IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. <i>Vaccine</i> , 2019, 37, 2322-2330.	3.8	9
28	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , 2020, 11, 984.	4.8	9
29	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.8	8
30	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	4.7	8
31	Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity. <i>MBio</i> , 2021, 12, e0174321.	4.1	7
32	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. <i>Nature Communications</i> , 2022, 13, 903.	12.8	7
33	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	6
34	Antibodies Tip the Balance Towards an HIV Cure. <i>Trends in Immunology</i> , 2019, 40, 375-377.	6.8	5
35	Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. <i>Journal of Immunology</i> , 2021, 206, 999-1012.	0.8	5
36	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. <i>Frontiers in Immunology</i> , 2020, 11, 626464.	4.8	4

#	ARTICLE	IF	CITATIONS
37	CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 757811.	4.8	0